Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Kezar Life Sciences, a clinical-stage biotechnology company, announced that CEO John Fowler will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on January 11, 2021, at 6:00 am EST on the company’s website. Kezar is focused on developing breakthrough treatments for immune-mediated and oncologic disorders, including KZR-616, a first-in-class immunoproteasome inhibitor, and KZR-261 for cancer treatment. An archived replay will be accessible for 90 days post-conference.

Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, being held on January 11-14, 2021.

The presentation will be available on Monday, January 11, 2021 at 6:00am EST and may be accessed at the “Events & Presentations” section of the Company’s website at https://www.kezarlifesciences.com/investors/news-events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via selective targets. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company’s protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005804/en/

FAQ

What is the date of the H.C. Wainwright Virtual BioConnect Conference for KZR?

The conference will be held from January 11-14, 2021.

Where can I access Kezar Life Sciences' presentation during the conference?

The presentation can be accessed on January 11, 2021, at 6:00 am EST at the 'Events & Presentations' section of their website.

What is KZR-616 and its significance?

KZR-616 is a first-in-class selective immunoproteasome inhibitor being evaluated for severe autoimmune diseases.

How long will the Kezar Life Sciences presentation be available online after the conference?

The archived replay of the presentation will be available for 90 days after the conference.

What type of disorders is Kezar Life Sciences targeting?

Kezar Life Sciences is developing treatments for immune-mediated and oncologic disorders.